百诚医药：BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征患者日间过度思睡治疗的临床试验批件

证券之星2025-05-12

证券之星消息，百诚医药(301096)05月12日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘你好，请问百诚医药1类药BIOS-0618片新批的临床试验进展如何，是否符合预期？

百诚医药回复：尊敬的投资者您好，BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡治疗的临床试验批件，后续相关进展请关注公司定期报告，感谢您的关注。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2534619297?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-12 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534619297","market":"hk","top_or_hot":-1,"title":"百诚医药：BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征患者日间过度思睡治疗的临床试验批件","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/301096\">百诚医药</a>(301096)05月12日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘你好，请问百诚医药1类药BIOS-0618片新批的临床试验进展如何，是否符合预期？</p><p>百诚医药回复：尊敬的投资者您好，BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡治疗的临床试验批件，后续相关进展请关注公司定期报告，感谢您的关注。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百诚医药：BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征患者日间过度思睡治疗的临床试验批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百诚医药：BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征患者日间过度思睡治疗的临床试验批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-12 15:07 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025051200013839.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，百诚医药(301096)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问百诚医药1类药BIOS-0618片新批的临床试验进展如何，是否符合预期？百诚医药回复：尊敬的投资者您好，BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡治疗的临床试验批件，后续相关进展请关注公司定期报告，感谢您的...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025051200013839.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"https://stock.stockstar.com/RB2025051200013839.shtml","article_id":"2534619297","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534619297","pubTimestamp":1747033642,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，百诚医药(301096)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问百诚医药1类药BIOS-0618片新批的临床试验进展如何，是否符合预期？百诚医药回复：尊敬的投资者您好，BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡治疗的临床试验批件，后续相关进展请关注公司定期报告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301096":"百诚医药","03347":"泰格医药","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","BK1576":"医药外包概念","BK0216":"研究试验"},"translate_title":"Baicheng Pharmaceutical: The clinical trial of BIOS-0618 went smoothly, and in April 2025, it obtained clinical trial approval for the treatment of excessive daytime sleepiness in patients with obstructive sleep apnea syndrome, a new indication","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301096":1,"03347":1},"content_text":"证券之星消息，百诚医药(301096)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问百诚医药1类药BIOS-0618片新批的临床试验进展如何，是否符合预期？百诚医药回复：尊敬的投资者您好，BIOS-0618临床试验顺利，2025年4月已获得适用于新增适应症阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡治疗的临床试验批件，后续相关进展请关注公司定期报告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2534619297","isCrawlerRequest":true}